Immune tolerance induction in patients with hemophilia A

Thrombosis Research

Volumn 127, Issue SUPPL. 1, 2011, Pages

  Astermark, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor VIII (FVIII); FVIII VWF concentrate; Hemophilia; Immune tolerance; von Willebrand factor (VWF)

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; NEUTRALIZING ANTIBODY; RITUXIMAB; VON WILLEBRAND FACTOR;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE MUTATION; HEMOPHILIA A; HEREDITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK REDUCTION; STEREOSPECIFICITY; TREATMENT OUTCOME;

AGED; COAGULANTS; DRUG COMBINATIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; MUTATION; VON WILLEBRAND FACTOR;

EID: 78651406684     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.10.006     Document Type: Article

References (21)

1. J. Astermark, J. Voorberg, H. Lenk, D. DiMichele, A. Shapiro, and G. Tjönnfjord Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro Haemophilia 9 2003 567 572
2. J. Astermark, M. Morado, A. Rocino, H.M. van den Berg, M. von Depka, and A. Gringeri Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors Haemophilia 12 2006 363 371
3. J. Addiego, C. Kasper, C. Abildgaard, M. Hilgartner, J. Lusher, and B. Glader Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII Lancet 342 1993 462 464
4. J. Wight, and S. Paisley The epidemiology of inhibitors in haemophilia A: a systematic review Haemophilia 9 2003 418 435
5. G. Mariani, B. Kroner Immune Tolerance Study Group (ITSG) Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success Haematologica 86 2001 1186 1193
6. D.M. DiMichele, and B.L. Kroner The North American Immune Tolerance Registry: practices, outcomes, outcome predictors Thromb Haemost 87 2002 52 57
7. H. Lenk The German registry of ITT in hemophilia: 1999 update Haematologica 85 10 Suppl 2000 45 47
8. H.H. Brackmann, and J. Gormsen Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder Lancet 2 1977 933
9. M. Behrmann, J. Pasi, J.-M. Saint-Remy, R. Kottischke, and M. Kloft Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model Thromb Haemost 88 2002 221 229
10. B.M. Reipert, P.M.W. van den Helden, H.-P. Schwarz, and C. Hausl Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors Br J Haematol 136 2006 12 25
11. D. DiMichele The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy Haemophilia 15 2009 320 328
12. P.W. Collins, M. Mathias, J. Hanley, D. Keeling, R. Keenan, and M. Laffan Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort J Thromb Haemost 7 2009 787 794
13. M. Franchini Rituximab in the treatment of adult acquired hemophilia A: a systematic review Crit Rev Oncol Hematol 63 2007 47 52
14. A. Chuansumrit, Y. Moonsup, N. Sirachainan, S. Benjaponpitak, A. Suebsangad, and P. Wongwerawattanakoon The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate Blood Coagul Fibrinolysis 19 2008 208 211
15. Y. Alvarado, X. Yao, C. Jumper, F. Hardwicke, N. D'Cunha, and E. Cobos Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature Clin Appl Thromb Hemost 13 2007 443 448
16. R. Stasi, M. Brunetti, E. Stipa, and S. Amadori Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia Blood 103 2004 4424 4428
17. D.M. DiMichele, I. Goldberg, and M. Foulkes International Immune Tolerance Study Group. International prospective randomized immune tolerance (ITI) study: preliminary results of the therapeutic efficacy and safety Haemophilia 16 Suppl 4 2010 29
18. A. Coppola, M. Maragaglione, E. Santagostino, A. Rocino, E. Grandone, and P.M. Mannucci Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors J Thromb Haemost 7 2009 1809 1815
19. W. Kreuz, C. Escuriola Ettingshausen, G. Auerswald, P. Heidemann, B. Kemkes-Mattes, and R. Schneppenheim Immune tolerance induction (ITI) in haemophilia A - patients with inhibitors - the choice of concentrate affecting success Haematologica 86 Suppl 4 2001 16 22
20. T. Suzuki, M. Arai, K. Amano, K. Kagawa, and K. Fukutake Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor Thromb Haemost 76 1996 749 754
21. A. Gringeri VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study Haemophilia 13 Suppl 5 2007 73 77